While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Media formats available:
Details
Presenters
Related
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Vera Bril, MD
Professor of Medicine
University of Toronto
Toronto, CanadaDr. Bril has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Contracted Researcher: Alexion, ArgenX, Momenta, UCB
Advisor/Consultant: Alexion, ArgenX, Momenta, UCBFaculty:
Hans Katzberg, MD
Professor of Neurology
University of Toronto
Toronto, CanadaDr. Katzberg has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisor/Consultant: Akcea, Alexion, Alnylam, Argenx, AstraZeneca, Behring, CSL, Dianthus, Dyne, Grifols, Janssen, Merz, Octapharma, Roche, Takeda, Terumo, UCB
Contracted Researcher: Argenx, TakedaNicholas J. Silvestri, MD
Professor of Neurology
University at Buffalo Jacobs School of Medicine
and Biomedical Sciences
Buffalo NYDr. Silvestri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Advisor/Consultant: Alexion, Amgen, Argenx, EMD Serono, Immunovant, Johnson & Johnson, UCB
Reviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Barry Fiedel, PhD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Delineate the pathophysiologic, clinical, and laboratory features that determine the diagnosis and etiology of generalized myasthenia gravis (gMG)
- Describe a pathophysiology-based framework for the treatment of gMG with current and future biologic therapies
Target Audience
This activity has been designed to meet the educational needs of neurologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with gMG.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-047-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until April 2, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson and Johnson companies.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
videoTreatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Show more